Hormone Replacement Therapy: What the Science Actually Shows and Why So Many Women Have Been Misled

Few topics in women’s health have caused more confusion, more fear, and more unnecessary suffering than hormone replacement therapy. Millions of women have been told that estrogen causes breast cancer. Millions more have been told to simply endure the symptoms of menopause because the risks of treatment outweigh the benefits. Many have been denied the one intervention that could meaningfully protect their brain, their heart, their bones, and their quality of life during and after the most significant hormonal transition of their lives.

The science does not support that approach. And the story of how we got here is one of the most important and most frustrating episodes in the history of medicine.

As a performance and optimization specialist deeply committed to women’s health through our Thrive Women’s Health Program, I want to walk through what the evidence actually shows, correct the most damaging misconceptions, and give women the information they need to have an informed conversation with their physicians.

1. What Estrogen Does and Why Its Loss Is So Significant

Estrogen does not simply support reproduction. It is a master regulatory hormone with receptors throughout the body: in the brain, the heart, the bones, the skin, the joints, and the vascular endothelium. Its effects are broad, systemic, and significant.

During a woman’s reproductive years, estrogen rises and falls in a monthly cycle that supports ovulation, maintains uterine health, protects cardiovascular function, supports bone density, and modulates brain chemistry in ways that affect mood, memory, and cognitive function. When menopause arrives, estrogen does not gradually decline the way testosterone declines in men over decades. It plummets to approximately one percent of its pre-menopausal level. Not a modest reduction. A near-complete withdrawal.

This is one of the most underappreciated facts in women’s health. Most women understand that menopause involves a decline in estrogen. Most do not understand the magnitude of that decline, or its consequences across every organ system that estrogen was supporting.

The symptoms most commonly associated with menopause, hot flashes and night sweats, are the most visible but not the most consequential. The full constellation includes palpitations, cognitive decline, joint pains, sleep disturbances, depression, and vaginal atrophy. These symptoms are not minor inconveniences that last a few months. The average duration of menopausal symptoms is seven and a half years. For some women, symptoms continue for ten, fifteen, or more years. And the downstream consequences of estrogen withdrawal on brain health, cardiovascular health, and bone health compound across decades.

2. The Women’s Health Initiative: What It Actually Showed

In 2002, the Women’s Health Initiative published findings that caused an immediate and dramatic collapse in HRT use. Women were told that HRT increased their risk of breast cancer. Within two years, HRT use in the United States dropped from 22 percent to 10 percent of the age-appropriate population. By 2010, it had fallen to 5 percent. Tens of thousands of women were taken off hormones abruptly. Millions of newly menopausal women were told not to start.

The problem is that the WHI findings were misrepresented, misinterpreted, and widely applied to populations the study was never designed to reflect.

The study population had an average age of 63, approximately ten years past menopause. Seventy percent were overweight or obese. More than forty percent were smokers. Many had hypertension. Symptomatic women, those most likely to benefit from HRT, were specifically excluded from the study because researchers feared they would drop out if randomized to placebo. This was never an ideal, healthy, newly menopausal population. It was an older, less healthy population in whom the risks of any intervention would be higher.

More critically, the headline finding that HRT increased breast cancer risk was not statistically significant. The reported 26 percent relative increase did not meet the threshold for statistical significance. By the standards of science, a finding that could have occurred by chance alone is not a finding. Yet it was presented in a press release before the data were published, picked up by every major news outlet, and turned into the basis for a generation of clinical guidelines.

The absolute numbers make the misrepresentation even clearer. Even accepting the reported relative increase at face value, the absolute increase in breast cancer risk was 0.9 cases per 1,000 women. Less than one woman per thousand. And even that modest absolute number was likely explained not by a genuine increase in the HRT group but by a lower than expected rate in the placebo group, many of whom had previously been on HRT and therefore carried a lower baseline risk.

The WHI investigators have since walked back their conclusions substantially. What they have not done is acknowledge that the damage done by their original press release, the millions of women denied effective treatment for menopausal symptoms and denied protection against cardiovascular disease, Alzheimer’s disease, osteoporosis, and colon cancer, was largely unnecessary.

3.The Real Risk Women Should Be Thinking About: Heart Disease

One of the most consequential distortions in the HRT story involves the comparison between breast cancer and heart disease. Most women, when asked, say they fear breast cancer far more than heart disease. The statistics tell a very different story.

One in four women die of heart disease. The lifetime risk of dying from breast cancer is approximately one in thirty-eight. Women are ten times more likely to die from heart disease than from breast cancer. More than half of all women will develop cardiovascular disease in their lifetime. Two-thirds of women who die suddenly from coronary heart disease had no previous symptoms. Heart disease kills more women than the next sixteen causes of death combined, including all forms of cancer.

And estrogen is one of the most potent protectors of cardiovascular health available to women. Multiple studies have shown that HRT, started at or around the time of menopause in women without pre-existing cardiovascular disease, reduces the risk of heart disease by up to 50 percent. The WHI’s reported increase in cardiovascular events was seen in an older, less healthy population, and primarily during the first year of starting therapy. It was not seen in women who begin HRT around the time of menopause.

The critical clinical concept here is the timing hypothesis, sometimes called the window of opportunity. Starting HRT within the first ten years of menopause, before significant arterial changes have accumulated, is associated with cardiovascular benefit. Starting it much later, in women with pre-existing subclinical or clinical atherosclerosis, carries different risks. The distinction matters enormously, and it was obscured by the WHI’s use of an older, predominantly postmenopausal population.

4. Alzheimer’s Disease: The Underappreciated Catastrophe

Women are twice as likely to die of Alzheimer’s disease as men. This disparity is not fully explained by longevity. The more likely explanation involves the abrupt estrogen withdrawal that women experience at menopause, compared to the gradual testosterone decline that men experience across decades.

Estrogen is neuroprotective. It supports brain energy metabolism, reduces inflammatory signaling in the brain, and appears to protect the neural architecture that degrades in Alzheimer’s disease. Studies examining HRT’s impact on Alzheimer’s risk have found reductions of between 20 and 50 percent depending on the study and the population. For a disease with no effective treatment and a 100 percent fatality rate, a preventive reduction of that magnitude is extraordinary.

To put this in perspective: for every woman diagnosed with breast cancer over age 60, two women are diagnosed with Alzheimer’s disease. The cure rate for early-diagnosed breast cancer is now approximately 90 percent. The cure rate for Alzheimer’s disease is zero. The one potential preventive intervention is estrogen, and it has been withheld from millions of women based on a misrepresented statistic.

At RMRM, brain health is central to our approach to women’s longevity through the Thrive Women’s Health Program. The perimenopause transition is a critical neurological window, and the decisions made about hormone therapy during that window have lasting consequences for cognitive health.

5. The Progesterone Question

One nuance that deserves careful attention is the distinction between different types of progesterone. Women with a uterus need progesterone alongside estrogen to protect against uterine cancer. The WHI used a synthetic progestogen called medroxyprogesterone acetate, or MPA, which is biochemically different from naturally occurring progesterone.

The modest increase in breast cancer risk seen in the WHI’s combination arm, though not statistically significant, has been attributed by some researchers to MPA rather than to estrogen.

Women who need progesterone should have a conversation with their physician about which form is most appropriate. This is exactly the individualized, evidence-based approach we take with every patient at RMRM.

6. The Real Risks of HRT

A complete discussion requires acknowledging the genuine risks of HRT, which are real but smaller than the narrative created by the WHI.

Venous thromboembolism and pulmonary embolism are the most significant genuine risks. The absolute increase is small, but for women with pre-existing conditions that increase clotting risk, this is a meaningful consideration before starting therapy.

Gallstones and cholecystectomy rates are modestly elevated in women on HRT.

Women with pre-existing cardiovascular disease, particularly those with significant atherosclerosis, should approach HRT with caution, particularly if starting more than ten years past menopause.

These risks deserve honest discussion between a patient and her physician. They do not justify the blanket refusal to discuss or prescribe HRT that many women have encountered.

7. What Every Woman Should Know

The benefits of HRT, for women who start at or around the time of menopause without pre-existing cardiovascular disease, substantially outweigh the risks for most women. This is the conclusion of a careful review of the evidence by researchers and clinicians who have no financial interest in the outcome.

HRT is not appropriate for every woman in every situation. But the current standard of reflexive refusal, or of prescribing the smallest dose for the shortest possible time without examining the evidence for long-term benefit, has caused and continues to cause enormous, preventable harm.

Every woman approaching perimenopause or menopause deserves a thorough, evidence-based conversation with a clinician who understands this literature. That conversation should include her individual risk factors, her symptoms, her family history, and her goals for long-term health.

At RMRM, our Thrive Women’s Health Program is built specifically to have that conversation and to build personalized hormone strategies grounded in the best available evidence. Explore our hormone therapy options, our diagnostics and therapies, and our annual membership.

Want to start Thriving?

Frequently Asked Questions By Patients

Patient Success Stories

These patient success stories reflect our commitment to treating the root biological causes of knee pain, rather than just masking symptoms. Our mission is to help you restore function, stay active, and age stronger, so you can move better and live better every day.